Ligustroflavone alleviates chronic kidney disease by inhibiting ferroptosis through the GSK3β/NRF2 signaling pathway
In summary, ligustroflavone inhibits ferroptosis in RTECs and confers protection in CKD. These findings suggest that ligustroflavone holds promise as a potential therapeutic agent for CKD.
Authors
- Jiayu Song (ORCID: https://orcid.org/0000-0003-0316-0774)
- Sutianyi Li
- Yunwen Yang
- Shaofan Wang
- Mingyue Chen
- Wen Zhang
- Yaru Wang
Institutions
- Nanjing University of Chinese Medicine (CN)
- Anhui Medical University (CN)
- Nanjing General Hospital of Nanjing Military Command (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Yangzhou University (CN)
Publication Details
- Journal
- Redox Report
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1080/13510002.2026.2636421
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00